Last reviewed · How we verify
GZR4 Injection
GZR4 Injection is a glucagon receptor antagonist.
GZR4 Injection is a glucagon receptor antagonist. Used for Treatment of type 2 diabetes.
At a glance
| Generic name | GZR4 Injection |
|---|---|
| Also known as | Degludec, Icodec |
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of glucagon, a hormone that raises blood glucose levels, thereby lowering blood glucose levels in patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment (PHASE1)
- Comparison Study of Insulin GZR4 With Insulin Degludec (PHASE1)
- A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects (PHASE1)
- A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus (PHASE2)
- Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment (PHASE1)
- A Study of GZR4 Injection at Different Injection Sites (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GZR4 Injection CI brief — competitive landscape report
- GZR4 Injection updates RSS · CI watch RSS
- Gan and Lee Pharmaceuticals, USA portfolio CI